X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs LUPIN - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS LUPIN IPCA LABS/
LUPIN
 
P/E (TTM) x 29.3 40.8 71.7% View Chart
P/BV x 4.3 2.5 172.7% View Chart
Dividend Yield % 0.1 0.7 16.4%  

Financials

 IPCA LABS   LUPIN
EQUITY SHARE DATA
    IPCA LABS
Mar-18
LUPIN
Mar-18
IPCA LABS/
LUPIN
5-Yr Chart
Click to enlarge
High Rs6951,465 47.5%   
Low Rs400727 55.0%   
Sales per share (Unadj.) Rs260.2349.6 74.4%  
Earnings per share (Unadj.) Rs19.05.6 341.3%  
Cash flow per share (Unadj.) Rs33.129.6 111.8%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.20.5 40.0%  
Book value per share (Unadj.) Rs213.0300.3 70.9%  
Shares outstanding (eoy) m126.20452.08 27.9%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x2.13.1 67.1%   
Avg P/E ratio x28.9197.2 14.6%  
P/CF ratio (eoy) x16.637.1 44.7%  
Price / Book Value ratio x2.63.6 70.4%  
Dividend payout %5.390.0 5.9%   
Avg Mkt Cap Rs m69,120495,502 13.9%   
No. of employees `00013.317.0 77.8%   
Total wages/salary Rs m7,35928,647 25.7%   
Avg. sales/employee Rs Th2,477.49,273.6 26.7%   
Avg. wages/employee Rs Th555.21,681.0 33.0%   
Avg. net profit/employee Rs Th180.6147.4 122.5%   
INCOME DATA
Net Sales Rs m32,836158,042 20.8%  
Other income Rs m4181,504 27.8%   
Total revenues Rs m33,254159,545 20.8%   
Gross profit Rs m4,50531,475 14.3%  
Depreciation Rs m1,77710,859 16.4%   
Interest Rs m2402,044 11.8%   
Profit before tax Rs m2,90520,076 14.5%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m5112,885 17.7%   
Profit after tax Rs m2,3942,513 95.3%  
Gross profit margin %13.719.9 68.9%  
Effective tax rate %17.614.4 122.4%   
Net profit margin %7.31.6 458.6%  
BALANCE SHEET DATA
Current assets Rs m19,455122,095 15.9%   
Current liabilities Rs m10,07650,956 19.8%   
Net working cap to sales %28.645.0 63.5%  
Current ratio x1.92.4 80.6%  
Inventory Days Days9885 115.7%  
Debtors Days Days67120 55.8%  
Net fixed assets Rs m20,260129,876 15.6%   
Share capital Rs m252904 27.9%   
"Free" reserves Rs m26,633134,866 19.7%   
Net worth Rs m26,886135,771 19.8%   
Long term debt Rs m2,34064,245 3.6%   
Total assets Rs m41,173263,054 15.7%  
Interest coverage x13.110.8 121.0%   
Debt to equity ratio x0.10.5 18.4%  
Sales to assets ratio x0.80.6 132.7%   
Return on assets %6.41.7 369.4%  
Return on equity %8.91.9 481.2%  
Return on capital %10.83.7 289.3%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64253,141 29.4%   
Fx outflow Rs m4,88419,335 25.3%   
Net fx Rs m10,75933,807 31.8%   
CASH FLOW
From Operations Rs m3,41117,512 19.5%  
From Investments Rs m-1,354-14,073 9.6%  
From Financial Activity Rs m-1,304-14,921 8.7%  
Net Cashflow Rs m753-11,482 -6.6%  

Share Holding

Indian Promoters % 45.9 46.6 98.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 31.9 79.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.1 172.3%  
Shareholders   36,892 98,259 37.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ORCHID PHARMA LTD  CIPLA  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 17, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PANACEA BIOTECH COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS